• 보험의학회지
• /
• 제30권1호
• /
• pp.11-20
• /
• 2011

Both the enterically transmitted forms of viral hepatitis, hepatitis A and E are self-limited and do not cause chroni chepatitis. Chronic hepatitis occurs in patients with hepatitis B and C as well as in patients with chronic hepatitis D superimposed on chronic hepatitis B. Chronic hepatitis such as hepatitis B or C is important in terms of insurance underwriting and claims. General review of hepatitis B and C was performed in this article.

• 보험의학회지
• /
• 제2권1호
• /
• pp.34-36
• /
• 1985

Korea is an endemic area of chronic hepatitis in the world. Liver cirrhosis and liver cell carcinoma, presumed to be related to such chronic hepatitis, are the major causes of death in this country. The purpose of this study is disclosing the sources of chronic hepatitis in Korea establishing its histologic characteristics, disclosing the patterns of progression in chronic hepatitis, delineating its prognosis and finally speculating its etiology. The study group was composed of 183 patients with biopsy-proven acute icteric viral hepaticis, 32 patients with biopsy- proven anicteric hepatitis and 260 patients with biopsy- proven chronic hepatitis. These patients submitted to long-term follow-up by means of liver needle biopsy and/or clinicolaboratory evaluation. The period of follow-up ranged from two months to 18 years. The histological features of the initial biopsy specimens of chronic hepatitis permitted a division of the cases cases into the following five types: Type I. Persisting portal hepatitis : so called persisting hepatitis 43 Type II. Chronic inactive hepatitis with incomplete strand septal fibrosis. This type has thin fibrotic septation in addition to Type I with portal sclerosis 38 Type III. Chronic active periportal hepatitis(CAPH) : so called aggressive hepatitis, characterized by marked piecemeal necrosis. This type has been subdivided further into three groups: AB and C on the basis of histologic features. A CAPH without cirrhosis 15 B CAPH with cirrhosis 99 C CAPH with diffuse acinus type parenchymal nodules; characterized by rosette-forming micronodules 21 Type IV. Subacute hepatic necrosis; characterized by multilobular and/or bridging necrosis. 14 Type V. Persisting lobular hepatitis; characterized by spotty necrosis, which looks very similar to acute viral hepatitis. Such histologic changes should be persisted for more than six months 30 In Korea the main source of chronic hepatitis is the anicteric type. Of the chronic hepatitis observed in the hospital, Type IIIb was the most frequent in its incidence and occasionally exhibited development of hepatocellular carcinoma, but the mortality was highest in Type IIIc during the period of follow-up. Histologic characteristics of these five types suggest a spectrum of chronic hepatitis in Korea from an early and mild stage to advanced and fatal cirrhosis, which is occasionally associated with primary hepatic cell carcinoma. It seems that Type IV can be followed by flare-up of various stages of acute and chronic hepatitis with HBsAg and that many cases of liver cirrhosis prevalent in Korea occur through such an active process of Type IV. The etiology is not established, but in Korea it is mainly related to HBsAg.

• 가정∙방문간호학회지
• /
• 제22권1호
• /
• pp.69-77
• /
• 2015

Purposes: The purpose of the study was to evaluate knowledge of hepatitis C and compliance with therapeutic guidelines and their correlation. Methods: Participants included a total of 197 subjects with chronic hepatitis C from 4 general hospitals. Subjects were asked 25 items of knowledge on hepatitis C and 17 items of compliance with therapeutic guidelines. The collected data was analyzed for frequency, percentage, average, standard deviation, t-test, ANOVA and Pearson's correlation coefficient. with the help of SPSS 21.0 program. Results: The subject's knowledge on chronic hepatitis C expressed as percentage was 67.1%. Compliance of the research participants gained $3.96({\pm}0.76)$ points in general on a 5-point scale. Learned compliance was higher when the patients were 45 years old and over. female and with spouse. There was a statistically significantly positive correlation between knowledge and compliances. Conclusions: Development of educational programs requires consideration of patient characteristics, particularly education on the male patients under 45 years of age.

• 대한임상검사과학회지
• /
• 제45권1호
• /
• pp.9-15
• /
• 2013

Hepatitis B virus (HBV) infection has recently shown to be associated with diabetes mellitus. The objective of this study was to investigate the relationship between chronic hepatitis B and diabetes mellitus indicators. We evaluated anthropometry, metabolic syndrome risk factors, fasting glucose, HbA1c, and C-peptide among the normal and HBV subjects. The partial correlation and average comparison analysis were used to assess the independent association between chronic hepatitis B and diabetes mellitus indicators. Average comparisons of normal and HBV subjects were significantly different in fasting glucose (p<0.000), HbA1c (p<0.000), C-peptide (p<0.000), alanine transaminase (ALT) (p<0.000) and aspartate transaminase (AST) (p<0.000). We may suggest that HBV infection is related to diabetes mellitus indicators such as fasting glucose, HbA1c and C-peptide.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권12호
• /
• pp.5025-5030
• /
• 2015

Immunoregulatory cytokines have an influence on hepatitis C virus (HCV) infection outcome. This study aimed to determine whether single nucleotide polymorphisms (SNP) in IFN- ${\gamma}$ and IL-10 genes are associated with susceptibility and/or are markers of prognosis regarding chronic hepatitis C outcomes. IFN ${\gamma}$ (+874T/A) and IL-10 (-1082G/A) genotypes were determined in 75 HCV genotype 4 patients with different disease severities (chronic hepatitis, n=25, liver cirrhosis and hepatocellular carcinoma (HCC) on top of liver cirrhosis, n=50) and 25 healthy participants using allele-specific polymerase chain reaction. No statistical differences in allele or genotype distributions of IFN ${\gamma}$ and IL-10 genes were detected between patients and controls or between patientgroups. No significant difference in the frequency of IL-10 SNP at position -1082 or IFN-${\gamma}$ at position +874T/A was found between chronic HCV genotype 4 and with progression of disease severity in liver cirrhosis or HCC. In conclusion; interferon-${\gamma}$ and interleukin-10 gene polymorphisms are not predictors of disease progression in patients with chronic hepatitis C (Genotype-4).

• 한국수의병리학회:학술대회논문집
• /
• 한국수의병리학회 2003년도 추계학술대회초록집
• /
• pp.18-18
• /
• 2003

Hepatitis C virus (HCV) has become a major public health issue and is prevalent in most countries. HCV infection starts frequently without clinical symptoms, and progresses in the majority of patients (70 to 85％) to persistent viremia and chronic hepatitis including cirrhosis and hepatocellularcarcinoma (HCC) [1]. Alcohol is one of the independent cofactors accelerating the development of HCC in chronic hepatitis C patients. This is of great interest because a synergy between excessive alcohol intake and HCV infection has been documented in the development of HCC in chronic hepatitis C patients [2]. The aim of this study is to investigate liver changes in ethanol feeding HCV-transgenic (Tg) mouse and to establish an animal model system. (omitted)

• The Korean Journal of Physiology and Pharmacology
• /
• 제17권5호
• /
• pp.375-383
• /
• 2013

Hepatocellular carcinoma (HCC) related to hepatitis B virus (HBV) and hepatitis C virus (HCV) infections is thought to account for more than 80% of primary liver cancers. Both HBV and HCV can establish chronic liver inflammatory infections, altering hepatocyte and liver physiology with potential liver disease progression and HCC development. Cyclophilin A (CypA) has been identified as an essential host factor for the HCV replication by physically interacting with the HCV non structural protein NS5A that in turn interacts with RNA-dependent RNA polymerase NS5B. CypA, a cytosolic binding protein of the immunosuppressive drug cyclosporine A, is overexpressed in many cancer types and often associated with malignant transformation. Therefore, CypA can be a good target for molecular cancer therapy. Because of antiviral activity, the CypA inhibitors have been tested for the treatment of chronic hepatitis C. Nonimmunosuppressive Cyp inhibitors such as NIM811, SCY-635, and Alisporivir have attracted more interests for appropriating CypA for antiviral chemotherapeutic target on HCV infection. This review describes CypA inhibitors as a potential HCC treatment tool that is contrived by their obstructing chronic HCV infection and summarizes roles of CypA in cancer development.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권12호
• /
• pp.5917-5935
• /
• 2012

Background: Hepatitis C virus (HCV) causes acute and chronic human hepatitis infection and as such is an important global health problem. The virus was discovered in the USA in 1989 and it is now known that three to four million people are infected every year, WHO estimating that 3 percent of the 7 billion people worldwide being chronically infected. Humans are the natural hosts of HCV and this virus can eventually lead to permanent liver damage and carcinoma. HCV is a member of the Flaviviridae family and Hepacivirus genus. The diameter of the virus is about 50-60 nm and the virion contains a single-stranded positive RNA approximately 10,000 nucleotides in length and consisting of one ORF which is encapsulated by an external lipid envelope and icosahedral capsid. HCV is a heterogeneous virus, classified into 6 genotypes and more than 50 subtypes. Because of the genome variability, nucleotide sequences of genotypes differ by approximately 31-34%, and by 20-23% among subtypes. Quasi-species of mixed virus populations provide a survival advantage for the virus to create multiple variant genomes and a high rate of generation of variants to allow rapid selection of mutants for new environmental conditions. Direct contact with infected blood and blood products, sexual relationships and availability of injectable drugs have had remarkable effects on HCV epidemiology. Hundreds of thousands of people die each year from hepatitis and liver cancer caused by HCV virus infection. Approximately 80% of patients with acute hepatitis C progress into a chronic disease state leading to serious hepatic disorders, 10-20% of which develop chronic liver cirrhosis and hepatocellular carcinoma. The incubation period of HCV is 6-8 weeks and the infection is often asymptomatic so it is very hard to detect at early stages, making early treatment very difficult. Therefore, hepatitis C is called a "silent disease". Neutralizing antibodies are produced against several HCV proteins during infection but the virus mutates to escape from antibodies. Some patients with chronic hepatitis C may have some symptoms such as fatigue, muscle aches, nausea and pain. Autoimmune and immunecomplex-mediated diseases have also been reported with chronic HCV infection.

• 대한간학회지
• /
• 제24권4호
• /
• pp.351-357
• /
• 2018

The advent of novel, direct-acting antiviral (DAA) regimens for hepatitis C virus (HCV) infection has revolutionized its treatment by producing a sustained virologic response of more than 95% with few side effects and no comorbidities in the general population. Until recently, ideal DAA regimens have not been available to patients with severe renal impairment and end-stage renal disease because there are limited data on the pharmacokinetics, safety, and efficacy of treatment in this unique population. In a hemodialysis context, identifying patients in need of treatment and preventing HCV transmission may also be a matter of concern. Recently published studies suggest that a combination of paritaprevir/ritonavir/ombitasvir and dasabuvir, elbasvir/grazoprevir, or glecaprevir/pibrentasvir successfully treats HCV infection in chronic kidney disease stage 4 or 5 patients with or without hemodialysis.

• Journal of Acupuncture Research
• /
• 제20권1호
• /
• pp.244-253
• /
• 2003

Objective : Interferon-alpha and Rivabirin are much used at the same time to treat Chronical C viral hepatitis. But interferon caused lots of unexpected side effects, Acupuncture Treatment for them will be an alternative plan. Methods : We first posed questions to a 4 year-old man who ha skin flare, fatigue, itching, insomnia, pronounced a diagnosis based on overall of symptoms and signs and then treated Acupuncture, Moxibustion and Electroacupuncture. We acupunctured a BL17, BL18, BL20 and removed it at once. We electroacupunctured at GV20, Yin tang(Ex-HN3) form 20 minutes, acupunctured at Bi yi(鼻翼, Extra-point), S36, P6. Pizhengge(脾定格) was acupunctured for 10 minutes. Results : The symptoms of fatigue, insomnia, itching are reduced after acupuncture treatments and they made a person keep interferon treatment on. Conclusions : We confirmed that acupuncture treatments make a patient of chronic C viral hepatitis reduce and improve side effects of interferon treatment. We should keep on studying the various and efficient method of acupuncture treatment to improve living quality and treatment efficiency of patients.